Torgem Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 16-12-2024
- Paid Up Capital ₹ 1.00 M
as on 16-12-2024
- Company Age 11 Year, 4 Days
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 7.90 M
as on 16-12-2024
- Revenue 18.56%
(FY 2020)
- Profit 0.40%
(FY 2020)
- Ebitda 4.34%
(FY 2020)
- Net Worth 28.82%
(FY 2020)
- Total Assets 19.49%
(FY 2020)
About Torgem Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹7.90 M.
Shilpi Devi and Jitendra Chaubey serve as directors at the Company.
- CIN/LLPIN
U74997MH2013PTC251196
- Company No.
251196
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
19 Dec 2013
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Raigarh, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Torgem Pharmaceuticals Private Limited offer?
Torgem Pharmaceuticals Private Limited offers a wide range of products and services, including Cleaning Liquids & Wipes, Glass Cleaners.
Who are the key members and board of directors at Torgem Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shilpi Devi  | Director | 19-Dec-2013 | Current |
| Jitendra Chaubey | Director | 19-Dec-2013 | Current |
Financial Performance of Torgem Pharmaceuticals.
Torgem Pharmaceuticals Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 18.56% increase. The company also saw a slight improvement in profitability, with a 0.4% increase in profit. The company's net worth Soared by an impressive increase of 28.82%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Torgem Pharmaceuticals?
In 2020, Torgem Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 20 Sep 2023 | ₹5.00 M | Open |
Others Creation Date: 05 Jun 2020 | ₹0.40 M | Open |
Others Creation Date: 28 Aug 2015 | ₹2.50 M | Open |
How Many Employees Work at Torgem Pharmaceuticals?
Unlock and access historical data on people associated with Torgem Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Torgem Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Torgem Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
